Finanzen von Axsome Therapeutics, Inc. (AXSM)AXSMAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. (AXSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SUNOSI milestone revenue, accounting for 100.2% of total sales, equivalent to $218.92M. Other significant revenue streams include Auvelitv and Sunosi. Understanding this composition is critical for investors evaluating how AXSM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Axsome Therapeutics, Inc. maintains a gross margin of 93.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.42%, while the net margin is -23.50%. These profitability ratios, combined with a Return on Equity (ROE) of -245.10%, provide a clear picture of how effectively AXSM converts its operational activities into shareholder value.

In the context of the broader market, AXSM competes directly with industry leaders such as ARWR and CAI. With a market capitalization of $8.47B, it holds a significant position in the sector. When comparing efficiency, AXSM's gross margin of 93.06% stands against ARWR's 100.00% and CAI's 68.10%. Such benchmarking helps identify whether Axsome Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Axsome's revenue has shown significant growth, with Q2 2026 revenue reaching $218.4 million, a 51% increase year-over-year, but it still reported a net loss of $51.3 million in the same quarter. The gross margin remains strong at 93.06%, reflecting efficient cost management.